clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Sacroiliitis D058566 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Vallejo Camazón N et al. [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. 2002 Rev Esp Cardiol pmid:12199987
Garza González E et al. [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. 2007 Rev Esp Enferm Dig pmid:17417917
de Artaza Varasa T et al. [Effect of Helicobacter pylori eradication on patients with functional dyspepsia]. 2008 Rev Esp Enferm Dig pmid:19025303
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Rodrigo Sáez L et al. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. 1997 Rev Esp Enferm Dig pmid:9115827
Sainz R et al. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. 1999 Rev Esp Enferm Dig pmid:10601771
Rojas Feria M et al. Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. 2000 Rev Esp Enferm Dig pmid:11468787
Rodríguez Téllez M et al. Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. 1999 Rev Esp Enferm Dig pmid:10491487
Gisbert JP [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. 1999 Rev Esp Enferm Dig pmid:10231305
González Carro P et al. [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. 1998 Rev Esp Enferm Dig pmid:9780793
Boixeda D et al. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success. 2003 Rev Esp Enferm Dig pmid:12760710
Gisbert JP et al. Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. 2003 Rev Esp Enferm Dig pmid:12760719
Torres-Debat ME et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. 2009 Rev Esp Enferm Dig pmid:20001152
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Castro-Fernández M et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. 2009 Rev Esp Enferm Dig pmid:19630462
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Carabias ML et al. [Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. 2001 Rev Esp Quimioter pmid:11704772
Gordillo RM et al. [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)]. 2003 Rev Esp Quimioter pmid:12750758
Cantón E et al. [In vitro susceptibility to antibiotics and the most common Streptococcus pneumoniae serotypes: a multicenter study]. 2005 Rev Esp Quimioter pmid:15915232
Agudo S et al. Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. 2011 Rev Esp Quimioter pmid:21412667
Díaz-Reganon J et al. [Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors]. 2006 Rev Esp Quimioter pmid:16688289
Agudo S et al. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. 2009 Rev Esp Quimioter pmid:19544100
Orellana MA and Gómez-Lus ML [Which is the best empirical treatment in patients with urethritis?]. 2011 Rev Esp Quimioter pmid:21947096
Vega AE et al. [Detection of resistance to clarithromycin in clinical isolates of Helicobacter pylori from children and adults]. 2003 Rev Esp Quimioter pmid:12750757
Ruiz-Aragón J et al. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria]. 2007 Rev Esp Quimioter pmid:18563216
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Gálvez-Múgica MA et al. [Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14961134
Alarcón T et al. [In vitro activity of clarithromycin and metronidazole against Helicobacter pylori in different incubation atmospheres]. 2002 Rev Esp Quimioter pmid:12587039
Rubio-Terrés C et al. [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin]. 2003 Rev Esp Quimioter pmid:14702121
Abad-Santos F et al. [Meta-analysis of clarithromycin compared with other antimicrobial drugs in the treatment of upper respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14702124
Alarcón T et al. [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. 2005 Rev Esp Quimioter pmid:16446791
Abasolo Osinaga E et al. [Dispensation and cost of antimicrobials in Spain (1998-2000)]. 2005 Rev Esp Quimioter pmid:16446789
Orden Martínez B et al. [Haemophilus spp. antimicrobial susceptibility in Health Area 6 in Madrid, Spain (2000-2004)]. 2005 Rev Esp Quimioter pmid:16130040
Vakil N Helicobacter pylori treatment: is sequential or quadruple therapy the answer? 2008 Rev Gastroenterol Disord pmid:18641590
Guarner J and Mohar A [The association between Helicobacter pylori and gastric neoplasia. Epidemiologic evidence]. 2000 Oct-Dec Rev Gastroenterol Mex pmid:11464618
Ladrón de Guevara L et al. [Evaluation of the symptomatology and quality of life in functional dyspepsia before and after Helicobacter pylori eradication treatment]. 2004 Oct-Dec Rev Gastroenterol Mex pmid:15765971
Dehesa M et al. [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. 1998 Apr-Jun Rev Gastroenterol Mex pmid:10068730
Ramírez Ramos A [Treatment of Helicobacter pylori infection: current status]. 1995 Rev Gastroenterol Peru pmid:8520021
Rodríguez W et al. [Omeprazole, amoxicillin and clarithromycin in the treatment of helicobacterpylori, in 7 and 10-day regimens]. 2003 Jul-Sep Rev Gastroenterol Peru pmid:14532918
Velasco Benítez CA and Amorocho Pérez RD [Treatment of gastritis-associated Helicobacter pylori infection in children]. 2002 Apr-Jun Rev Gastroenterol Peru pmid:12098744
Silva FM et al. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. 2001 Jan-Feb Rev Hosp Clin Fac Med Sao Paulo pmid:11378678
Pinto LA et al. Effect of clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease. 2004 Rev Hosp Clin Fac Med Sao Paulo pmid:15286828
Souza R et al. Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. 2002 Jul-Aug Rev Hosp Clin Fac Med Sao Paulo pmid:12244337
[Zeclar, a new antibiotic (clarithromycin 250 mg from Abbott laboratories]. 1994 Rev Infirm pmid:7652424
Dautzenberg B et al. [Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection]. 1994 Rev Mal Respir pmid:8041990
Camara B et al. [Infection due to Mycobacterium malmoense in an immunocompetent patient]. 2008 Rev Mal Respir pmid:19106910
Payen MC et al. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. 1997 Rev Mal Respir pmid:9496599
Gomez-Abreo D et al. [Chronic necrotizing pulmonary aspergillosis following an infection by Mycobacterium malmoense]. 2012 Rev Mal Respir pmid:22440310